BioSpace News Archive

OneTrust, the largest and most widely used dedicated privacy management platform today announced ResMed, a world-leading connected health company with more than 10 million cloud-connectable devices for daily remote patient monitoring, selected OneTrust to power global privacy compliance.

Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and other serious diseases, today announced the appointment of Noreen Henig, M.D., and Edward Kaye, M.D., to the company’s board of directors.

Nordic Nanovector ASA announces its results for the second quarter and first half 2019.

Swedish Orphan Biovitrum AB has entered into an agreement to sell a US Food and Drug Administration Priority Review Voucher to AstraZeneca for a total cash consideration of USD 95 M.

Upfront payment and equity investment made to secure option on antibody for ophthalmology

Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, today announced the promotion of Gary Yeung, CFA, to chief operating and financial officer, as well as the appointment of David Chacko, M.D., to chief business officer. Les Brail, Ph.D., has been appointed vice president of clinical development, and Karen Gilmore, CPA, has been appointed vice president of finance.

MYOS RENS Technology Inc. (“MYOS” or “the Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today the launch of the Yolked® Rose Bowl Stadium Sweepstakes,

Theragun, the leader in percussive therapy, announced the opening of Theragun Reset™ in Los Angeles, the world’s first-ever brick and mortar percussive therapy experience.

DSFederal, an award-winning, woman-owned business, has expanded its team to include Coursera, Dale-Carnegie, and Georgetown University to support its new $100 million Integrated Services Blanket Purchase Agreement (BPA) that serves as the FDA’s primary contract vehicle for training support services, learning management, program and project management, and human capital managemen

ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration